Survival of Ph/bcr-abl–positive patients after BMT in chronic phase (n = 152): (A) According to pretransplant therapy as randomized (46 hydroxyurea, 25 busulfan and 81 IFN [±chemotherapy] patients; alive by May 31, 1998: 28 [61%] hydroxyurea, 12 [48%] busulfan, and 48 [59%] IFN patients); 5-year survival after IFN pretreatment is 57% (95% confidence interval [CI]: 46 to 69), after hydroxyurea 60% (CI: 46 to 75) and after busulfan 60% (CI: 40 to 79). These differences are not significant. (B) According to type of transplant in chronic phase patients only (n = 152; 104 related, 48 unrelated transplants). Five-year survival after related transplants 57% (95% CI: 47 to 66), after unrelated transplants 61% (CI: 46 to 77).